Text Size

Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

This study has been completed.
Sponsor:
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00059449
First received: April 25, 2003
Last updated: January 12, 2010
Last verified: January 2010
History of Changes
  Purpose

Necrotizing enterocolitis (NEC) is a serious gastrointestinal disorder that primarily affects preterm infants. About 10% of babies less than 32 weeks gestation at birth will develop it. Overall, 30% of babies who develop NEC will die from it, with many others developing long term gastrointestinal problems. The most important factor in its development is a premature intestinal tract. Epidermal growth factor (EGF) is an important growth factor in the development and maintenance of the gastrointestinal tract. This study will look for a relationship between EGF levels in premature babies and the development of NEC.


Condition
Necrotizing Enterocolitis
Premature Birth

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Role of Epidermal Growth Factor (EGF) in Development of Necrotizing Enterocolitis

Resource links provided by NLM:

Drug Information available for: Urogastrone
U.S. FDA Resources

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Estimated Enrollment: 372
  Eligibility

Ages Eligible for Study:   up to 72 Hours
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Gestational Age greater than 23 weeks at birth
  • Birth weight greater than 500 grams
  • Age less than 72 hours of life
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00059449

Locations
United States, Ohio
Good Samaritan Hospital
Cincinnati, Ohio, United States, 45220
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
University Hospital
Cincinnati, Ohio, United States, 45229
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00059449     History of Changes
Other Study ID Numbers: EGFDNE (completed)
Study First Received: April 25, 2003
Last Updated: January 12, 2010
Health Authority: United States: Federal Government

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Enterocolitis

Additional relevant MeSH terms:
Enterocolitis
Premature Birth
Enterocolitis, Necrotizing
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
 Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Mitogens
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013